# Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

> **NCT01897779** · PHASE1 · COMPLETED · sponsor: **Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)** · enrollment: 94 (actual)

## Conditions studied

- Healthy Volunteers
- Bacterial Infections

## Interventions

- **DRUG:** RPX7009
- **DRUG:** RPX2014
- **DRUG:** Placebo
- **DRUG:** Combination RPX7009 and RPX2014

## Key facts

- **NCT ID:** NCT01897779
- **Lead sponsor:** Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897779, "Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01897779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*